3Q EARNINGS: Will Actavis, CEO Saunders continue deal streak?
This article was originally published in Scrip
Executive Summary
Actavis won't let its massive debt position – $15.1bn as of the third quarter of 2014 – get in the way of its dealmaking track record, including large transactions, which may or may not include the specialty biopharmaceutical company Allergan.
You may also be interested in...
‘Open Science’ In Action: Allergan Exercises Option For Motus After Gastroparesis Study
Allergan will pay $200m to exercise its option to buy Motus Therapeutics (formerly Rhythm Health) after what the pharma described as a successful Phase IIb study for relamorelin in diabetic gastroparesis.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.
Finance Watch: Another Bevy Of VC Mega-Rounds, Including $175m For Capstan
Private Company Edition: Capstan and Engrail raised $175m and $157m, respectively, in series B venture capital rounds in addition to Madrigal’s $400m-plus launch and Clasp’s $150m series A.